The article offers information on the use of biosimilars for cancer treatment and patient education. Topics discussed include role of efficacy or safety, mechanism of action, and condition or approved indications; Filgrastim-sndz for patients with chemotherapy-induced myelosuppression; and cost-effective of biosimilars to frequently prescribed biologic agents.